Diligence memo · auto-generated · as of July 2, 2026
Amyris, Inc.
Amyris, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Amyris, Inc. operates in Manufacturing, based in EMERYVILLE. Amyris is a vertically integrated biomanufacturing company that uses renewable biological chemistry to create, customize, and manufacture high-performance molecules and advance a more prosperous and resilient world.
Sub-sector tags: biotech, climate/cleantech.
Capital & rounds (filed)filed
Amyris, Inc. has raised $1.6B in disclosed capital across 46 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2020-06-05.
Most recent recorded round closed around 2022-09-13.
Filings read as a recurring offering program rather than a clean venture-stage ladder — interpret stage labels and step-ups with that in mind.
Valuation (modeled)modeled
Provath models Amyris, Inc. at approximately $77M (range $46M–$131M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Series D+ Manufacturing companies in 2022–2024 (10 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 3.8 yr ago; this sector typically re-raises about every 12 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 25.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Manufacturing peers (3257 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Lotus Technology Inc., Arrival, Newlight Technologies, Inc., Filtration Group Equity Llc, BPCP NSA Holdings, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.
Recurring-offering pattern: stage-based valuation has lower applicability.